Esco Lifesciences raises $200m in Vivo Capital, Novo Holdings-led round

Esco Lifesciences raises $200m in Vivo Capital, Novo Holdings-led round

Photo by Louis Reed on Unsplash

Singapore-based Esco Lifesciences, which provides products and services for the life sciences and healthcare industries, has announced the closure of an oversubscribed $200 million Series A and crossover round led by Vivo Capital and Novo Holdings.  

The round saw participation from new investors including EDBI, which is the investment arm of the Singapore Economic Development Board, and China Investment Corporation.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter